10-Q: Privia Health Reports Strong Q3 Growth, Boosted by Acquisitions

Privia Health Group, Inc. announced robust financial results for the third quarter and first nine months of 2025, driven by significant revenue increases, expanded provider network, and strategic acquisitions.

Summary

• Revenue for the three months ended September 30, 2025, increased by 32.5% to $580.4 million, up from $437.9 million in the prior year period.
• Net income attributable to Privia Health Group, Inc. for Q3 2025 rose by 94.1% to $6.9 million, compared to $3.5 million in Q3 2024.
• For the nine months ended September 30, 2025, total revenue grew 24.0% to $1.58 billion, with net income attributable to Privia Health Group, Inc. increasing 37.9% to $13.8 million.
• Implemented Providers increased by 13.1% year-over-year to 5,250 as of September 30, 2025.
• Attributed Lives grew by 12.8% year-over-year to 1.406 million as of September 30, 2025.
• Practice Collections for Q3 2025 increased 27.1% to $940.4 million, and for the nine months, they rose 19.6% to $2.60 billion.
• Adjusted EBITDA for Q3 2025 surged 61.6% to $38.2 million, and for the nine months, it increased 43.5% to $94.1 million.
• The company entered the Arizona market on April 8, 2025, through the acquisition of a 51% ownership interest in PMG-AZ, which contributed $37.0 million in revenue from the acquisition date through September 30, 2025.
• Received $156.9 million from the Centers for Medicare and Medicaid Services in October 2025 for 2024 MSSP shared savings, with approximately $88.4 million to be disbursed to providers.
• Entered into a definitive agreement to acquire an ACO business from Evolent Health, Inc. for $100.0 million in cash at closing and up to an additional $13.0 million, expected to close in Q4 2025.

Sentiment

Score: 8

Explanation: The filing indicates very strong financial and operational performance, with significant growth in revenue, net income, and key metrics like providers and attributed lives. Strategic acquisitions and positive shared savings performance further bolster the positive outlook. While cash decreased due to acquisitions, this is an investment for future growth. The Rule 10b5-1 plans are pre-scheduled and not necessarily indicative of negative sentiment.

Positives

• Strong revenue growth of 32.5% for the three months and 24.0% for the nine months ended September 30, 2025, indicating robust business expansion.
• Significant increase in net income attributable to Privia Health Group, Inc. by 94.1% for the three months and 37.9% for the nine months, demonstrating improved profitability.
• Adjusted EBITDA saw substantial growth of 61.6% for the three months and 43.5% for the nine months, reflecting enhanced operational efficiency.
• Growth in key operational metrics: Implemented Providers increased 13.1% to 5,250 and Attributed Lives increased 12.8% to 1.406 million, indicating successful market penetration and patient engagement.
• Successful expansion into new markets, including the acquisition of PMG-AZ, contributing to revenue growth and geographic diversification.
• Positive performance in Value Based Care (VBC) programs, with shared savings revenue increasing by 68.6% for the three months and 39.5% for the nine months, partly due to a change in estimate related to the Shared Savings accrual.
• Capitated revenue increased significantly by 70.3% for the three months and 47.1% for the nine months, driven by increased Attributed Lives and improved contract terms.
• The company has no outstanding debt under its $125 million Revolving Credit Facility as of September 30, 2025, indicating a healthy liquidity position.

Negatives

• Cash and cash equivalents decreased from $491.1 million at December 31, 2024, to $441.4 million at September 30, 2025, primarily due to business acquisitions.
• Provider expense increased by 35.3% for the three months and 26.2% for the nine months, outpacing revenue growth in the three-month period, though this is largely tied to increased FFS-patient care revenue and provider growth.
• Care Margin as a percentage of revenue decreased to 21.6% for the three months ended September 30, 2025, from 23.2% in the prior year, and to 21.9% for the nine months from 23.2%, indicating strategic investments are growing faster than revenue percentage-wise.
• Two executive officers adopted Rule 10b5-1 trading plans for selling a significant number of shares (1,875,000 for Shawn Morris and 139,005 for David Mountcastle).

Risks

• The heavily regulated healthcare industry poses risks, and non-compliance with extensive applicable healthcare laws and government regulations could result in adverse financial impacts, operational changes, or reputational harm.
• The complexity of the legal framework governing relationships with Medical Groups and Privia Providers, including those not owned by the company, could lead to legal challenges or shifting interpretations of laws, requiring significant operational changes.
• The execution of the company's growth strategy may not prove viable, and expected results may not be realized.
• Difficulties in timely implementing the proprietary end-to-end, cloud-based technology solution for Privia Physicians and new Medical Groups could hinder growth.
• High competition in the industry and failure to effectively compete, including by innovating and evolving service offerings, could adversely affect the business.
• Challenges in successfully establishing a presence in new geographic markets could limit expansion.
• Failures or service disruptions at key third-party vendors, such as the primary EMR vendor athenahealth, Inc., could impact the Privia Technology Solution.
• Potential decreases in reimbursement rates by governmental and third-party payers, changes to payment terms, or challenges in negotiating and retaining favorable contracts with private third-party payers could reduce revenue.
• Changes impacting the patient population, such as insured individuals moving to health plans with greater coverage exclusions or restrictions or narrower networks, and increases in uninsured or underinsured patients, could affect financial performance.
• Compliance with complex and changing federal and state privacy and security laws and regulations related to personal and protected health information, including HIPAA, could have financial and operational impacts.
• Actual and potential security threats, cybersecurity incidents, or privacy/data breaches involving the company, its vendors, or other third parties pose risks.
• The continued availability of a qualified workforce, including staff at Medical Groups, and continued upward pressure on compensation for such workforce, could impact costs and operations.

Future Outlook

The company expects continued long-term growth through investments in sales and marketing, technology, and operations. It anticipates increasing its provider base in existing and new markets, leading to incremental economics and leveraging existing brand and infrastructure. The company also aims to increase patient volume through improved patient experience and referrals, and to accelerate the adoption of Value Based Care reimbursement by enhancing VBC capabilities and executing initiatives for superior quality metrics and lower cost of care.

Management Comments

• Management believes that the benefits of increased protection from anti-takeover provisions outweigh the disadvantages of discouraging proposals, as negotiation could result in improved terms.
• Management considers Care Margin, Platform Contribution, Platform Contribution Margin, Adjusted EBITDA, and Adjusted EBITDA Margin useful non-GAAP measures for evaluating operating performance and assessing business health.
• Management expects Care Margin to grow year-over-year in absolute dollars as the provider base expands, and care management and shared savings economics in VBC arrangements to improve on a per patient basis.
• Management anticipates that net cash provided by operating activities, together with available cash on hand, should be adequate to meet anticipated cash requirements for both the short and long term.

Industry Context

The healthcare industry is undergoing a significant shift towards value-based care (VBC) models, moving away from traditional fee-for-service. Privia Health's strategy of enabling physicians to succeed in VBC arrangements aligns well with this trend, positioning it to capitalize on evolving reimbursement environments. The company's expansion into new markets and its focus on increasing attributed patient lives in VBC programs reflect a proactive approach to industry changes, particularly given the regulatory and utilization headwinds in Medicare Advantage, which prompted renegotiation of capitation agreements in early 2024.

Comparison to Industry Standards

• The company's reported 13.1% increase in Implemented Providers and 12.8% increase in Attributed Lives demonstrate strong growth, which is competitive within the physician-enablement and value-based care sectors. Companies like Aledade and Oak Street Health (now part of CVS Health) also focus on expanding provider networks and attributed lives in VBC, and Privia's growth rates suggest effective execution in a competitive landscape.
• The 61.6% increase in Adjusted EBITDA for Q3 2025 is a robust performance indicator, often exceeding typical growth rates for established healthcare service providers, and suggests strong operating leverage and successful integration of new acquisitions.
• The acquisition of an ACO business from Evolent Health, Inc. for $100.0 million, with potential additional earn-outs, is a strategic move to expand VBC capabilities, similar to how larger healthcare entities like UnitedHealth Group (Optum) or Humana acquire and integrate physician groups and value-based care platforms to enhance their market position and care delivery models.
• The company's reported 96% provider retention rate is a strong indicator of platform satisfaction and stability, often exceeding industry averages for physician practice management organizations, which can face challenges in retaining independent physicians amidst consolidation trends.

Corporate Governance

Legal Proceedings

• The company is currently involved in, and may in the future become involved in, legal proceedings, claims, and investigations in the ordinary course of business, including medical malpractice and consumer claims.
• Management does not believe that the final outcome of any current matters is reasonably likely to have a material adverse effect on the business, financial condition, or results of operations.
• Such proceedings, claims, and investigations may nonetheless impose a significant burden on management and employees and be costly to defend, regardless of final outcomes.

Related Party Transactions

• A member of the Board is also a member of the board of trustees of Novant Health, Inc., with whom the company has a strategic alignment agreement (Equity Alignment Agreement) through its subsidiary ChoiceHealth, Inc. (Novant Sub). No shares have been issued to Novant Sub under this agreement as of September 30, 2025.

Stakeholder Impact

• Shareholders: Positive financial results (revenue, net income, EBITDA growth) and strategic acquisitions could lead to increased shareholder value. However, the decrease in cash due to acquisitions and the Rule 10b5-1 trading plans by executives could introduce some uncertainty.
• Employees: Continued growth and expansion into new markets suggest job stability and potential for new opportunities. Increased stock-based compensation expense indicates ongoing incentives for employees.
• Customers (Patients): Expansion of the provider network and focus on Value Based Care aim to deliver better outcomes, lower costs, and improved patient experience.
• Suppliers/Vendors: Continued growth and acquisitions may lead to increased demand for services from key vendors, such as athenahealth, Inc., but also highlight reliance on these third parties.
• Creditors: The company's strong cash position and no outstanding debt under its revolving credit facility indicate a healthy financial standing, reducing credit risk.

Next Steps

• Complete the formal valuation analysis for the PMG-AZ acquisition to finalize the allocation of purchase price.
• Close the acquisition of the ACO business from Evolent Health, Inc. in the fourth quarter of 2025, subject to regulatory approvals and customary closing conditions.
• Continue focusing on long-term growth through investments in sales and marketing, technology stack, and operations.
• Further enhance VBC capabilities and execute initiatives to deliver next-generation access, superior quality metrics, and lower cost of care.
• Shawn Morris's trading plan for the sale of 1,875,000 securities will commence on December 8, 2025, and end on August 31, 2026.
• David Mountcastle's trading plan for the sale of 139,005 securities will commence on December 1, 2025, and end on November 30, 2026.

Key Dates

Recommendation

The filing demonstrates exceptional financial and operational performance, with significant year-over-year growth across all key metrics including revenue, net income, and Adjusted EBITDA. The expansion of Implemented Providers and Attributed Lives, coupled with strategic acquisitions like PMG-AZ and the planned acquisition of Evolent Health's ACO business, indicates a robust growth trajectory and successful execution of its market expansion strategy. The strong performance in Value Based Care programs, including substantial shared savings, further validates the company's business model and its alignment with evolving healthcare trends. While cash decreased due to acquisition activity, this represents strategic investment for future growth rather than operational weakness. The absence of outstanding debt on its credit facility also highlights financial prudence. Despite the Rule 10b5-1 plans, the overall picture is one of strong momentum and positive outlook, making it a compelling 'strong buy' for investors seeking growth in the healthcare sector.

Keywords

Healthcare, Physician-enablement, Value-based care, VBC, Medical Group, SEC filing, Quarterly report, Financial results, Revenue growth, Adjusted EBITDA, Acquisition, Implemented Providers, Attributed Lives, Shared savings, Capitated revenue, PRVA, Nasdaq